## For Research Use Only


## HER2/ErbB2 Polyclonal antibody Catalog Number: 18299-1-AP Featured Product 79 Publication

Featured Product 79 Publications


proteinter Antibodies | ELISA kits | Proteins www.ptglab.com

Basic Information	Catalog Number: 18299-1-AP	GenBank Accession Number: BC167147	Purification Method: Antigen affinity purification	
	Size:	GeneID (NCBI):	Recommended Dilutions:	
	150ul , Concentration: 700 ug/ml by	2064	WB: 1:2000-1:12000	
	Nanodrop;	UNIPROT ID:	IP: 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate	
	Source: Rabbit	P04626	IHC: 1:300-1:1200	
	Isotype:	Full Name: v-erb-b2 erythroblastic leukemia	IF-Fro: 1:50-1:500	
	lgG	viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)		
		Calculated MW:		
		138 kDa		
		Observed MW: 185 kDa		
Applications	Tested Applications:	Positive Controls:		
	WB, IHC, IF-Fro, IP, ELISA	WB:4T1 ce	ells, SGC-7901 cells, MCF-7 cells, HeLa cell	
	Cited Applications: WB, IHC, IF, IP	IP : SGC-7901 cells,		
	Species Specificity:	IHC : huma	n breast cancer tissue,	
	human, mouse	IF-Fro : mo	IF-Fro : mouse breast cancer,	
	Cited Species: human, mouse, rat			
	Note-IHC: suggested antigen n TE buffer pH 9.0; (*) Alternati retrieval may be performed w buffer pH 6.0	vely, antigen		
	HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand-binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas. This antibody raised against a synthesized peptide corresponding to 1237-1255aa of human HER2 recognizes the 185-kDa full-length glycosylated form and other lower molecular-mass forms of HER2, including the truncated form.			
Background Information	therefore cannot bind growth factors. members to form a heterodimer, stab downstream signalling pathways, su phosphatidylinositol-3 kinase. Ampl cancers, including breast and ovariar other carcinomas. This antibody raise recognizes the 185-kDa full-length g	f receptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancin ch as those involving mitogen-activ ification and/or overexpression of H n tumors. HER2 is a therapeutic targe ed against a synthesized peptide co	b ligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of rated protein kinase and IER2 have been reported in numerous at for the treatment of breast cancer and responding to 1237-1255aa of human HER	
	therefore cannot bind growth factors. members to form a heterodimer, stat downstream signalling pathways, su phosphatidylinositol-3 kinase. Ampl cancers, including breast and ovariar other carcinomas. This antibody raise recognizes the 185-kDa full-length g truncated form.	f receptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancin ch as those involving mitogen-activ ification and/or overexpression of H n tumors. HER2 is a therapeutic targe ed against a synthesized peptide co Lycosylated form and other lower m	o ligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of rated protein kinase and HER2 have been reported in numerous it for the treatment of breast cancer and responding to 1237-1255aa of human HER olecular-mass forms of HER2, including the	
	downstream signalling pathways, su phosphatidylinositol-3 kinase. Ampl cancers, including breast and ovariar other carcinomas. This antibody raise recognizes the 185-kDa full-length g truncated form.	f receptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancing ch as those involving mitogen-activ ification and/or overexpression of H tumors. HER2 is a therapeutic targe ed against a synthesized peptide co by cosylated form and other lower m bmed ID Journal	b ligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of ated protein kinase and HER2 have been reported in numerous et for the treatment of breast cancer and responding to 1237-1255aa of human HER olecular-mass forms of HER2, including the Application	
Background Information	glowth factor (EUP) receptor family ctherefore cannot bind growth factors.members to form a heterodimer, stabdownstream signalling pathways, suphosphatidylinositol-3 kinase. Amplcancers, including breast and ovariarother carcinomas. This antibody raiserecognizes the 185-kDa full-length gtruncated form.AuthorPuSamusi Adediran36	f receptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancir ch as those involving mitogen-activ ification and/or overexpression of tumors. HER2 is a therapeutic targe ed against a synthesized peptide co lycosylated form and other lower m bmed ID Journal 230550 Cancers (Basel)	bligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of ated protein kinase and IER2 have been reported in numerous et for the treatment of breast cancer and responding to 1237-1255aa of human HER olecular-mass forms of HER2, including the Application WB	
	glowth factor (EUP) receptor family Ctherefore cannot bind growth factors.members to form a heterodimer, stabdownstream signalling pathways, suphosphatidylinositol-3 kinase. Amplcancers, including breast and ovariarother carcinomas. This antibody raiserecognizes the 185-kDa full-length gtruncated form.AuthorPuSamusi Adediran36Zhirui Zhang27	f receptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancir ch as those involving mitogen-activ ification and/or overexpression of tumors. HER2 is a therapeutic targe ed against a synthesized peptide co cycosylated form and other lower m bmed ID Journal 230550 Cancers (Basel)	bligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of ated protein kinase and IER2 have been reported in numerous et for the treatment of breast cancer and responding to 1237-1255aa of human HER olecular-mass forms of HER2, including the Application WB	
	glowth factor (EUP) receptor family Ctherefore cannot bind growth factors.members to form a heterodimer, stabdownstream signalling pathways, suphosphatidylinositol-3 kinase. Amplcancers, including breast and ovariarother carcinomas. This antibody raiserecognizes the 185-kDa full-length gtruncated form.AuthorPuSamusi Adediran36Zhirui Zhang27	f receptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancing ch as those involving mitogen-activi ification and/or overexpression of H in tumors. HER2 is a therapeutic targe ad against a synthesized peptide co lycosylated form and other lower m bmed ID Journal 230550 Cancers (Basel) 658586 J Exp Clin Cancer	b ligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of rated protein kinase and IER2 have been reported in numerous et for the treatment of breast cancer and responding to 1237-1255aa of human HEF olecular-mass forms of HER2, including the Application WB Res WB	
	glowth factor (EUP) receptor family C   therefore cannot bind growth factors.   members to form a heterodimer, stat   downstream signalling pathways, su   phosphatidylinositol-3 kinase. Ampl   cancers, including breast and ovariar   other carcinomas. This antibody raise   recognizes the 185-kDa full-length gr   truncated form.   Author Pu   Samusi Adediran 36   Zhirui Zhang 27   Yangcenzi Xie 36   Storage: Storage Buffer:   PBS with 0.02% sodium azide and 50	freceptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancir ch as those involving mitogen-activ ification and/or overexpression of a tumors. HER2 is a therapeutic targe ed against a synthesized peptide co lycosylated form and other lower m bmed ID Journal 230550 Cancers (Basel) 658586 J Exp Clin Cancer 069700 Anal Chem	b ligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of rated protein kinase and IER2 have been reported in numerous et for the treatment of breast cancer and responding to 1237-1255aa of human HEF olecular-mass forms of HER2, including the Application WB Res WB	
Notable Publications	glowdriactor (EUP) receptor raining C   therefore cannot bind growth factors.   members to form a heterodimer, stat   downstream signalling pathways, su   phosphatidylinositol-3 kinase. Ampl   cancers, including breast and ovariar   other carcinomas. This antibody raise   recognizes the 185-kDa full-length g   truncated form.   Author Pu   Samusi Adediran 36   Zhirui Zhang 27   Yangcenzi Xie 36   Storage: Storage Buffer:	freceptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancir ch as those involving mitogen-activ ification and/or overexpression of a tumors. HER2 is a therapeutic targe ed against a synthesized peptide co lycosylated form and other lower m bmed ID Journal 230550 Cancers (Basel) 658586 J Exp Clin Cancer 069700 Anal Chem	b ligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of rated protein kinase and IER2 have been reported in numerous et for the treatment of breast cancer and responding to 1237-1255aa of human HER olecular-mass forms of HER2, including the Application WB Res WB	
Notable Publications	glowdriactor (EUP) receptor rainity Ctherefore cannot bind growth factors.members to form a heterodimer, statdownstream signalling pathways, suphosphatidylinositol-3 kinase. Amplcancers, including breast and ovariarother carcinomas. This antibody raiserecognizes the 185-kDa full-length gtruncated form.AuthorPuSamusi Adediran36Zhirui Zhang27Yangcenzi Xie36Storage:Storage Buffer:PBS with 0.02% sodium azide and 50Aliquoting is unnecessary for -20°C s	freceptor tyrosine kinases. It has no However, it does bind tightly to oth bilizing ligand binding and enhancin ch as those involving mitogen-activ ification and/or overexpression of h tumors. HER2 is a therapeutic targe ed against a synthesized peptide co lycosylated form and other lower m bmed ID Journal 230550 Cancers (Basel) 658586 J Exp Clin Cancer 069700 Anal Chem er shipment. % glycerol, pH7.3 torage	b ligand-binding domain of its own and er ligand-bound EGF receptor family ng kinase-mediated activation of rated protein kinase and IER2 have been reported in numerous et for the treatment of breast cancer and responding to 1237-1255aa of human HEI olecular-mass forms of HER2, including th Application WB Res WB	


## Selected Validation Data




Various lysates were subjected to SDS PAGE followed by western blot with 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:6000 incubated at room temperature for 1.5 hours.




WB result of HER2/ErbB2 antibody (18299-1-AP; 1:20000; incubated at room temperature for 1.5 hours) with sh-Control and sh-HER2/ErbB2 transfected MCF-7 cells.




Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:600 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunohistochemical analysis of paraffinembedded human breast cancer tissue slide using 18299-1-AP (HER2/ErbB2 antibody) at dilution of 1:600 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



IP result of anti-HER2/ErbB2 (IP:18299-1-AP, 5ug; Detection:18299-1-AP 1:500) with SGC-7901 cells lysate 2400ug.



Immunofluorescent analysis of (4% PFA) fixed frozen OCT-embedded mouse breast cancer using HER2/ErbB2 antibody (18299-1-AP) at dilution of 1:200 and CoraLite@488-Conjugated Goat Anti-Rabbit IgG(H+L) (SA00013-2).